TapewireFind a company

person · Reporting owner

Azamian Bobak R.

Disclosed activity across 1 company

Tapewire entity
1864
SEC CIK
0001827672

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Tarsus Pharmaceuticals, Inc.TARS · Entity 1836Director · President/CEO and Board ChairSeptember 04, 2026September 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Tarsus Pharmaceuticals, Inc.

Report date September 04, 2026 · Filed September 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy the Bobak Azamian Living Trust established April 16, 2018827,991 Last balance in matching sequence After 2026-09-04 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2026-09-04 · Sale · Disposed 7,100 · Balance 830,891

F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.

F2: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $90.00 to $90.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Row 2 · 2026-09-04 · Sale · Disposed 2,900 · Balance 827,991

F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.

F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $91.06 to $91.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Common StockSEC Table I · non-derivativeDirect33,421 Reported balance Holding disclosure · report date 2026-09-04 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 33,421

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.

F2: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $90.00 to $90.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $91.06 to $91.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 01, 2021 Filed Nov 3, 2021 22:55 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 800 $28.21 $22,568.00
Disclosure

SEC source: 0001819790-21-000041 · wf-form4_163598012144660.xml · nonDerivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,209,939

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $28.10 to $28.27. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
November 01, 2021 Filed Nov 3, 2021 22:55 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 5,033 $27.76 $139,716.08
Disclosure

SEC source: 0001819790-21-000041 · wf-form4_163598012144660.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,210,739

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $27.10 to $28.09. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
October 12, 2021 Filed Oct 14, 2021 20:44 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 4,698 $26.44 $124,215.12
Disclosure

SEC source: 0001819790-21-000037 · wf-form4_163424427780477.xml · nonDerivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,215,772

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.05 to $26.76. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
October 12, 2021 Filed Oct 14, 2021 20:44 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 833 $25.49 $21,233.17
Disclosure

SEC source: 0001819790-21-000037 · wf-form4_163424427780477.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,220,470

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.04 to $26.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
October 08, 2021 Filed Oct 12, 2021 22:43 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 302 $25.02 $7,555.44
Disclosure

SEC source: 0001819790-21-000033 · wf-form4_163407859702568.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,221,303

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.000 to $25.055. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
September 01, 2021 Filed Sep 3, 2021 21:51 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 100 $26.40 $2,640.00
Disclosure

SEC source: 0001827672-21-000002 · wf-form4_163070587277035.xml · nonDerivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,221,605

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
September 01, 2021 Filed Sep 3, 2021 21:51 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 5,733 $25.23 $144,660.79
Disclosure

SEC source: 0001827672-21-000002 · wf-form4_163070587277035.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,221,705

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.000 to $25.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
August 11, 2021 Filed Aug 12, 2021 21:26 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 1,917 $25.07 $48,061.11
Disclosure

SEC source: 0001209191-21-051191 · doc4.xml · nonDerivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,227,438

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.000 to $25.275. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
August 10, 2021 Filed Aug 12, 2021 21:26 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 103 $25.00 $2,575.00
Disclosure

SEC source: 0001209191-21-051191 · doc4.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,229,355

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
August 09, 2021 Filed Aug 10, 2021 20:53 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 100 $25.13 $2,513.00
Disclosure

SEC source: 0001209191-21-050626 · doc4.xml · nonDerivative · entry 3

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,229,458

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
August 09, 2021 Filed Aug 10, 2021 20:53 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 727 $25.00 $18,175.00
Disclosure

SEC source: 0001209191-21-050626 · doc4.xml · nonDerivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,229,558

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
August 06, 2021 Filed Aug 10, 2021 20:53 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 1,616 $25.00 $40,400.00
Disclosure

SEC source: 0001209191-21-050626 · doc4.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,230,285

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
August 05, 2021 Filed Aug 6, 2021 20:14 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 SaleCommon Stock 1,370 $25.00 $34,250.00
Disclosure

SEC source: 0001209191-21-050176 · doc4.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,231,901

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
January 07, 2021 Filed Jan 8, 2021 21:53 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantStock Option (right to buy) · Derivative 204,998 $0.00 Strike: $47.25 $0.00
Disclosure

SEC source: 0001209191-21-002738 · doc4.xml · derivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,998

Underlying: Common Stock · 204,998 shares

Expires 2031-01-06

F1 · derivative.exercise_date: 25% of the option shares shall vest on January 7, 2022, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 23:53 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 ConversionSeries B Preferred Stock · Derivative 1,750 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-055419 · doc4.xml · derivative · entry 4

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 23:53 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 ConversionSeries A Preferred Stock · Derivative 21,575 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-055419 · doc4.xml · derivative · entry 3

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 0

Underlying: Common Stock · 21,575 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 23:53 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 ConversionCommon Stock 1,750 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-055419 · doc4.xml · nonDerivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 23:53 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 ConversionCommon Stock 21,575 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-055419 · doc4.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,233,271

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.